Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 1999

View Archived Issues

1999 annual report reflects progress in clinical trials at Ono

New distamycin derivatives developed at Pharmacia & Upjohn for cancer Rx

Warner-Lambert discloses another series of anticoagulants

Ion channel-blocking antiarrhythmic and anesthetic agents from Nortran

First macrolide LHRH antagonists patented by Abbott

H. pylori vaccine comprising a chimeric protein designed by Korean scientists

Fatty acid analogues synthesized at Searle particularly useful for HIV infection

Novel 2-naphthylcarbapenems active against resistant staphylococci and Gram-negative pathogens

Collagenase-selective MMP inhibitors designed by British Biotech for arthritis

Investigational NNRTI proves safe and effective in early clinical trial in HIV-infected patients

Once-daily s.c. T-1249 may provide therapeutic levels in man according to animal data

In search of therapeutic alternatives for HIV resistance: in vitro studies with tipranavir

AGN-192024 is better than latanoprost for lowering diurnal IOP

Dainippon Ink & Chemicals begins clinical testing of allergy drug

Mycophenolate mofetil in the treatment of refractory uveitis

More promising results with abarelix in endometriosis

Leptin promotes weight loss in obese and lean adults

Glaxo Wellcome withdraws antibiotic due to safety concerns

Sanofi-Synthelabo discovers a promising new lead in the treatment of multiple sclerosis

Tamiflu approved in time for U.S. flu season

Vical receives orphan drug status for Allovectin-7

Positive results reported for Amylin's type II diabetes therapy

Scios begins patient enrollment in phase III Natrecor trial

Additional positive data reported for Cell Pathways' exisulind

CPMP gives favorable opinion on Taxotere for advanced non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...